| NAME |
DARIDOREXANT 50MG TAB,ORAL |
| VA GENERIC NAME |
DARIDOREXANT |
| DOSAGE FORM |
TAB,ORAL |
| FDA MED GUIDE |
Daridorexant_(Quviviq)_(2022).pdf |
| HAZARDOUS TO DISPOSE |
NO |
| ACTIVE INGREDIENTS |
|
| CS FEDERAL SCHEDULE |
Schedule IV |
| STRENGTH |
50 |
| SINGLE/MULTI SOURCE PRODUCT |
Multisource |
| UNITS |
MG |
| NATIONAL FORMULARY NAME |
DARIDOREXANT TAB,ORAL |
| CREATE DEFAULT POSSIBLE DOSAGE |
NO |
| POSSIBLE DOSAGES TO CREATE |
1x Possible Dosage |
| PACKAGE |
Both Inpatient and Outpatient |
| CODING SYSTEM |
|
| COPAY TIER |
-
- COPAY TIER LEVEL: 3
- COPAY EFFECTIVE DATE: 2022-04-21 00:00:00
|
| PGX ELIGIBLE |
NO |
| PGX SUPPRESSED |
NO |
| VA PRINT NAME |
DARIDOREXANT 50MG ORAL TAB |
| VA PRODUCT IDENTIFIER |
D1283 |
| TRANSMIT TO CMOP |
NO |
| VA DISPENSE UNIT |
TAB |
| MASTER ENTRY FOR VUID |
YES |
| VUID |
4041359 |
| EFFECTIVE DATE/TIME |
-
- 2022-04-21 00:00:00
- STATUS: ACTIVE
|
